How Biotech Cos. Can Utilize Synthetic Royalty Financing

By Todd Trattner and Ryan Murr · February 1, 2024, 5:31 PM EST

Following the capital markets boom fueled by the Fed's accommodating monetary policy in 2020 and 2021, the biotech sector suffered nearly a 50% drop over a 12-month period from February 2021...

To view the full article, register now.